EDIT vs VYGR
EDIT: A pioneering CRISPR gene editing company developing in vivo therapies for genetic diseases, with lead candidate EDIT-401 targeting hyperlipidemia through LDL receptor upregulation. VYGR: A gene therapy company developing AAV-based therapeutics and non-viral treatments for neurological diseases, relying heavily on partnership revenue while advancing early-stage clinical programs.
Side-by-side fundamentals
| Metric | EDIT | VYGR | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $2.78 | $3.10 | |
| Market cap as of 2026-07-23 | $421M | $187M | |
| PEG as of 2026-07-23 | n/a | -0.04 | |
| Net margin as of 2026-07-23 | -281.6% | -319.6% | EDIT higher |
| Operating margin as of 2026-07-23 | -281.3% | -349.2% | EDIT higher |
| ROE as of 2026-07-23 | -677.4% | -56.0% | VYGR higher |
| ROA as of 2026-07-23 | -58.3% | -43.1% | VYGR higher |
| Debt / equity as of 2026-07-23 | 12.40 | 0.00 | VYGR lower |
| Revenue growth (YoY) as of 2026-07-23 | +8.0% | -45.5% | EDIT higher |
| Revenue CAGR (3y) SEC XBRL | +27.1% | -0.4% | EDIT higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 2.08 | 1.31 | |
| 1-year return as of 2026-07-22 close | -8.3% | -1.9% | VYGR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.